Merck Abandons Plans to Pursue Anacetrapib

The investigational cholesterol-lowering drug is now the fourth CETP inhibitor to fall by the wayside.
Medscape Medical News

This post was syndicated from Medscape Medical News Headlines. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply